Continue Reading
Full article on Unknown
Moderna is the S&P 500's most shorted stock: Here's why
Market Intelligence Analysis
AI-Powered
Why This Matters
Moderna (MRNA) is the most shorted stock in the S&P 500, with potential market disruptors such as President Trump's healthcare cost plans and Pfizer's entry into the weight-loss drug space, affecting the pharmaceutical industry.
Market Impact
Market impact analysis based on bearish sentiment with 72% confidence.
Sentiment
Bearish
AI Confidence
72%
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.
Original article published by
Unknown
on November 24, 2025.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.